The UK’s Medicines and Healthcare products Regulatory Agency has approved 342 parallel import licences in 2026, marking a significant regulatory response to ongoing pharmaceutical supply challenges following Britain’s departure from the European Union. This licensing mechanism enables pharmaceutical companies to legally import medicines already approved in European Economic Area countries, providing essential supply chain flexibility while maintaining rigorous safety and quality standards.
Parallel importation has emerged as a critical pathway for sustaining medicine access in the post-Brexit landscape. The MHRA’s continued approval of these licences demonstrates the regulatory agency’s commitment to balancing pharmaceutical availability with stringent safety oversight. Each licence permits importation of specific pharmaceutical products from designated EU member states, addressing supply shortages and offering cost-effective alternatives. Despite increased administrative complexity and new regulatory barriers introduced by Brexit, this framework remains essential for ensuring uninterrupted patient access to medicines across the UK healthcare system.
Read the full article on GMJ Newsroom.
Was this article helpful?
